Clinical Effect of Qingbu Weijing Decoction on Patients Suffering from Stable Bronchiectasis Complicated with Airway Mucus Hypersecretion

YUAN Shasha; SHI Xia; WANG Bing; MIAO Qing

doi:10.13422/j.cnki.syfjx.20230192

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Qingbu Weijing Decoction on Patients Suffering from Stable Bronchiectasis Complicated with Airway Mucus Hypersecretion

更新时间：2022-12-08

- Clinical Effect of Qingbu Weijing Decoction on Patients Suffering from Stable Bronchiectasis Complicated with Airway Mucus Hypersecretion
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 1, Pages: 97-104(2023)
- 作者机构：
  
  中国中医科学院西苑医院，北京 100091
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20230192
  CLC： R242;R2-031;R256.1;R562.2+2
- Received：06 April 2022，
  
  Published Online：14 November 2022，
  
  Published：05 January 2023
- 稿件说明：
移动端阅览
袁沙沙,石霞,王冰等.清补苇茎汤治疗稳定期支气管扩张症伴气道黏液高分泌患者的临床疗效[J].中国实验方剂学杂志,2023,29(01):97-104.

YUAN Shasha,SHI Xia,WANG Bing,et al.Clinical Effect of Qingbu Weijing Decoction on Patients Suffering from Stable Bronchiectasis Complicated with Airway Mucus Hypersecretion[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):97-104.
袁沙沙,石霞,王冰等.清补苇茎汤治疗稳定期支气管扩张症伴气道黏液高分泌患者的临床疗效[J].中国实验方剂学杂志,2023,29(01):97-104. DOI： 10.13422/j.cnki.syfjx.20230192.

YUAN Shasha,SHI Xia,WANG Bing,et al.Clinical Effect of Qingbu Weijing Decoction on Patients Suffering from Stable Bronchiectasis Complicated with Airway Mucus Hypersecretion[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(01):97-104. DOI： 10.13422/j.cnki.syfjx.20230192.

摘要

目的

评价清补苇茎汤治疗稳定期支气管扩张症伴气道黏液高分泌（气阴两虚、痰热蕴肺型）患者的临床疗效。

方法

将80例稳定期支气管扩张症伴气道黏液高分泌患者随机分为观察组和对照组各40例。观察组失访1例，退出1例，完成38例；对照组失访1例，退出4例，完成35例。观察组口服清补苇茎汤颗粒剂，每日1剂，分2次服用。对照组口服羧甲司坦口服液，每次500 mg，每日3次。两组患者均进行健康教育及体位排痰。疗程12周，随访12个月。评价治疗后两组患者急性加重次数、咳嗽-咳痰评估问卷（CASA-Q）、中医证候积分、肺功能［呼气峰值流量（PEF）占预计值百分比（PEF%pred）、第1秒用力呼气容积占预计值百分比（FEV

%pred）、FEV

/用力肺活量（FVC）］及血清炎症因子［C反应蛋白（CRP）、肿瘤坏死因子-

（TNF-

）、白细胞介素-8（IL-8）、白细胞介素-10（IL-10）、中性粒细胞弹性蛋白酶（NE）］水平的变化。

结果

与对照组比较，观察组患者治疗12周及随访12月后急性加重次数显著降低（

0.01）。CASA-Q中的咳嗽症状域（COUS）评分，与本组治疗前比较，观察组在治疗4、8、12周后及随访3、6、9、12个月后COUS评分均增高，对照组在治疗期间增高，但在随访期间降低；治疗后，观察组COUS评分优于对照组（

0.05，

0.01）。咳嗽影响域（COUI）评分，与本组治疗前比较，观察组在治疗4、8、12后及随访3、6、9、12个月后COUI评分均增高，对照组该领域评分均降低；治疗后，观察组COUI评分明显优于对照组（

0.05，

0.01）。咳痰症状域（SPUS）评分，与本组治疗前比较，两组患者在治疗4、8、12周后及随访3、6、9、12个月后SPUS评分均增高；治疗后，观察组SPUS评分明显优于对照组（

0.05，

0.01）。咳痰影响域（SPUI）评分，与本组治疗前比较，观察组在治疗4、8、12周后及随访3、6、9、12个月后SPUI评分均增高，对照组在治疗期间增高，但在随访期间降低；治疗后，观察组随访3、6、9个月SPUI评分优于对照组（

0.05）。观察组中医证候疗效有效率优于对照组，但组间比较仅在治疗8周（

=3.868，

0.05）及随访3个月（

=6.510，

0.05）差异具有统计学意义。与本组治疗前比较，两组患者在治疗4、8、12周后及随访3、6、9、12个月后中医证候积分得分均显著降低（

0.01）；除治疗4周外，其余观察组均明显优于对照组（

0.05）。与本组治疗前比较，观察组患者的肺功能改善，其中PEF%pred组间及组内比较差异均具有统计学意义（

0.05）。观察组及对照组均可下调血清炎症因子水平，但与本组治疗前比较，仅观察组TNF-

、IL-8、IL-10、NE差异具有统计学意义（

0.05），IL-8组间比较差异具有统计学意义（

0.05）。

结论

清补苇茎汤治疗稳定期支气管扩张症伴气道黏液高分泌气阴两虚、痰热蕴肺型患者，可显著改善咳嗽咳痰症状及减少患者的反复急性加重，并可以下调血清炎症因子水平，一定程度改善患者肺功能。

Abstract

Objective

To evaluate the clinical efficacy of Qingbu Weijing decoction in the treatment of patients suffering from stable bronchiectasis complicated with airway mucus hypersecretion （Qi and Yin deficiency， phlegm heat accumulation in lung）.

Method

Eighty patients with stable bronchiectasis and airway mucus hypersecretion were randomly divided into an observation group and a control group， 40 in each group. In the observation group， 38 cases were finally included for 1 case was lost and 1 withdrew， while in the control group， 35 cases were finally included for 1 case was lost and 4 withdrew. The observation group was po administered with Qingbu Weijing decoction granules， 1 dose twice a day. The control group was treated with oral Carbocysteine Oral Solutioncarboxymethylstein， 500 mg each time for three times a day. Both groups received health education and postural drainage. After 12 weeks of treatment and 12 months of follow-up， the changes in the number of acute exacerbations， Cough and Sputum Assessment Questionnaire （CASA-Q）， traditional Chinese medicine （TCM） syndrome score， lung function ［percentage of peak expiratory flow （PEF） to estimated value （PEF% pred）， percentage of forced expiratory volume in one second to estimated value （FEV

%pred）， FEV

/forced vital capacity （FVC）］ and serum inflammatory factors ［C-reactive protein （CRP）， tumor necrosis factor-α （TNF-

）， interleukin -8 （IL-8）， interleukin -10 （IL-10）， neutrophil elastase （NE）］ levels in the two groups after treatment were evaluated.

Result

The number of acute exacerbations in the observation group was lower than that in the control group after 12 weeks of treatment and 12 months of follow-up （

0.01）. Compared with the condition before treatment， the cough symptom domain （COUS） score of CASA-Q in the observation group was increased after 4， 8， 12 weeks of treatment and 3， 6， 9， 12 months of follow-up， while the COUS score in the control group was increased during treatment but decreased during follow-up， with the observation group higher than the control group （

0.05，

0.01）. The cough influence domain （COUI） score in the observation group was higher than that before treatment at 4， 8， 12 weeks after treatment and 3， 6， 9， 12 months after follow-up， while the COUI score in the control group was lower than that before treatment， with the observation group superior to the control group （

0.05，

0.01）. In terms of sputum symptom domain （SPUS）， the two groups both had elevated SPUS score after 4， 8， 12 weeks of treatment and 3， 6， 9， 12 months of follow-up， but the observation group was better than the control group （

0.05，

0.01）. In terms of sputum influence domain （SPUI）， the observation group had elevated SPUI score after 4， 8， 12 weeks of treatment and 3， 6， 9， 12 months of follow-up， while the control group presented increased SPUI score during treatment but reduced score during follow-up， with the observation group higher than the control group at 3， 6， 9 months of follow-up （

0.05）. The observation group outweighed the control group in the effective rate， while difference was only observed between the two groups after 8 weeks of treatment （

=3.868，

0.05） and 3 months of follow-up （

=6.510，

0.05）. Compared with the condition before treatment， the TCM symptom score was lowered in both groups after 4， 8， and 12 weeks of treatment and 3， 6， 9， 12 months of follow-up （

0.01）， and except for 4 weeks of treatment， the observation group had more reduction than the control group （

0.05）. The pulmonary function of patients in the observation group was improved compared with the condition before treatment， and there was difference in PEF% pred in intergroup and intragroup comparisons （

0.05）. Both groups had reduced level of serum inflammatory factors， but difference was only observed in TNF-

， IL-8， IL-10 and NE in the observation group compared with those before treatment （

0.05）， and in IL-8 between the two groups （

0.05）.

Conclusion

Qingbu Weijing decoction in the treatment of stable bronchiectasis patients with airway mucus hypersecretion （Qi and Yin deficiency， phlegm and heat accumulation in lung） can significantly alleviate their cough and expectoration and reduce the repeated acute exacerbation， and can down-regulate the level of serum inflammatory factors， thereby improving the lung function of patients to a certain extent.

关键词

Keywords

references

支气管扩张症专家共识撰写协作组，中华医学会呼吸病学分会感染学组 . 中国成人支气管扩张症诊断与治疗专家共识［J］. 中华结核和呼吸杂志， 2021 ， 44 （ 4 ）： 311 - 321 .

慢性气道炎症性疾病气道黏液高分泌管理中国专家共识编 . 慢性气道炎症性疾病气道黏液高分泌管理中国专家共识［J］. 中华结核和呼吸杂志， 2015 ， 38 （ 10 ）： 723 - 729 .

PASTEUR M C ， BILTON D ， HILL A T . British Thoracic Society guideline for non-CF bronchiectasis ［J］. Thorax ， 2010 ， 65 （ Suppl 1 ）： i1 - i58 .

ALIBERTI S ， MASEFIELD S ， POLVERINO E ， et al . Research priorities in bronchiectasis：A consensus statement from the EMBARC Clinical Research Collaboration ［J］. Eur Respir J ， 2016 ， 48 （ 3 ）： 632 - 647 .

FAHY J V ， DICKEY B F . Airway mucus function and dysfunction ［J］. N Engl J Med ， 2010 ， 363 （ 23 ）： 2233 - 2247 .

CURRAN D R ， COHN L . Advances in mucous cell metaplasia：a plug for mucus as a therapeutic focus in chronic airway disease ［J］. Am J Respir Cell Mol Biol ， 2010 ， 42 （ 3 ）： 268 - 275 .

王冰，樊茂蓉，崔云，等 . 王书臣治疗支气管扩张症经验［J］. 中医杂志， 2017 ， 58 （ 8 ）： 647 - 650 .

ZHENG J P ， KANG J ， HUANG S G ， et al . Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease（PEACE Study）：Arandomized placebo-controlled study ［J］. Lancet ， 2008 ， 371 （ 9629 ）： 2013 - 2018 .

成人支气管扩张症诊治专家共识编写组 . 成人支气管扩张症诊治专家共识（2012版）［J］. 中华危重症医学杂志：电子版， 2012 ， 5 （ 5 ）： 20 - 30 .

HILL A T ， HAWORTH C S ， ALIBERTI S ， et al . Pulmonary exacerbation in adults with bronchiectasis：A consensus definition for clinical research ［J］. Eur Respir J ， 2017 ， 49 （ 6 ）： 1700051 .

中华中医药学会 . 中医内科常见病诊疗指南中医病证部分［M］. 北京：中国中医药出版社， 2008 ： 17 - 18 .

CRAWFORD B ， MONZ B ， HOHLFELD J ， et al . Development and validation of a cough and sputum assessment questionnaire ［J］. Respir Med ， 2008 ， 102 （ 11 ）： 1545 - 1555 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 ： 14-15，22-23 ， 65 .

周卜全，李新科 . 厄多司坦对老年支气管扩张症及黏液分泌过多患者的治疗效果［J］. 实用医学杂志， 2011 ， 27 （ 6 ）： 1066 - 1068 .

帅冬怡，廖慧娟 . 厄多司坦治疗老年支气管扩张症及黏液分泌过多患者的效果［J］. 中国老年学杂志， 2015 ， 35 （ 14 ）： 3943 - 3944 .

贾自力，闫菊，武明芬，等 . 羧甲司坦治疗支气管扩张疗效及对生活质量影响［J］. 中日友好医院学报， 2018 ， 32 （ 2 ）： 93 - 95 .

祖翡翠 . 长期使用羧甲司坦对支气管扩张患者急性发作频率和持续时间的影响［J］. 中国药物评价， 2021 ， 38 （ 5 ）： 445 - 448 .

李用粹 . 证治汇补［M］. 北京：中国中医药出版社， 1999 ： 61 - 62 .

张介宾 . 景岳全书［M］. 北京：人民卫生出版社， 1991 ： 672 - 675 .

张秉成 . 成方便读［M］. 北京：中国中医药出版社， 2002 ： 151 .

孙备 . 麦门冬汤对气道清除及分泌的影响［J］. 国外医学：中医中药分册， 2000 ， 22 （ 2 ）： 101 .

吴仪洛 . 本草从新［M］：河南科学技术出版社， 2017 ： 3 - 4 .

邓青南，周建龙，郭振辉，等 . 半夏提取物对气道黏液高分泌的影响［J］. 中国呼吸与危重监护杂志， 2009 ， 8 （ 5 ）： 477 - 481 .

童瑾，周向东 . 代表性祛痰中药提取物对气道黏液上皮细胞粘蛋白的影响［J］. 中药药理与临床， 2006 ， 22 （ 2 ）： 33 - 35 .

MONZ B U ， SACHS P ， MCDONALD J ， et al . Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis ［J］. Respir Med ， 2010 ， 104 （ 4 ）： 534 - 541 .

WOUTERS E F . Local and systemic inflammation in chronic obstructive pulmonary disease ［J］. Proc Am Thorac Soc ， 2005 ， 2 （ 1 ）： 26 - 33 .

PEREA L ， CANTÓ E ， SUAREZ-CUARTIN G ， et al . A cluster analysis of bronchiectasis patients based on the airway immune profile ［J］. Chest ， 2021 ， 159 （ 5 ）： 1758 - 1767 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advantages of Chinese Medicine in Improving Airway Mucus Hypersecretion in Stable Bronchiectasis Patients

Clinical Observation of Bupi Qingfei Decoction in Treatment of Bronchiectasis Colonized by Pseudomonas aeruginosa

Effect and Mechanism of Modified Si Junzitang Combined with Heat-sensitive Moxibustion on IL-17, IL-22, IL-1α and Cys-C in Serum and Exhale Breath Condensate of Patients with Chronic Obstructive Pulmonary Disease at Stable Stage

Clinical Efficacy of Modified Qingjin Huatan Tang on Bronchiectasis with Syndrome of Phlegm-heat Accumulating Lung at Acute Exacerbation

Effect and Mechanism of Modified Buzhong Yiqi Tang and Pursed-lips Breathing on Serum TNF-α, IL-8, IL-6, IL-1β and Cys-C in Patients at Stable Stage of COPD

Related Author

MIAO Qing

ZHANG Haiyan

SHI Xia

CUI Lixin

LI Guangsen

FAN Maorong

YUAN Shasha

WANG Bing

Related Institution

China Academy of Chinese Medical Sciences

Beijing University of Chinese Medicine

The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (TCM)

Jiangxi University of TCM

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰